https://ir.vyometx.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_d024ecc7eca47b6f52a71f1586e4b046/vyometx/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.vyometx.com/news-events/press-releases/detail/106/vyome-holdings-reports-first-quarter-2026-results-with-key-fda-filings-and-strong-balance-sheet Thu, 28 May 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/106/vyome-holdings-reports-first-quarter-2026-results-with-key-fda-filings-and-strong-balance-sheet https://ir.vyometx.com/news-events/press-releases/detail/105/vyome-strikes-deal-with-impetis-biosciences-opening-a-~57b-market-opportunity Tue, 12 May 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/105/vyome-strikes-deal-with-impetis-biosciences-opening-a-~57b-market-opportunity https://ir.vyometx.com/news-events/press-releases/detail/85/vyome-presents-transformational-vt-1953-phase-2-clinical-study-data-at-prestigious-aacr-2026 Wed, 22 Apr 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/85/vyome-presents-transformational-vt-1953-phase-2-clinical-study-data-at-prestigious-aacr-2026 https://ir.vyometx.com/news-events/press-releases/detail/86/vyome-to-present-compelling-phase-2-clinical-data-on-vt-1953-for-treatment-of-mfw-at-aacr-2026 Mon, 06 Apr 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/86/vyome-to-present-compelling-phase-2-clinical-data-on-vt-1953-for-treatment-of-mfw-at-aacr-2026 https://ir.vyometx.com/news-events/press-releases/detail/87/vyome-reports-transformational-2025-results-company-well-positioned-for-breakout-phase Thu, 26 Mar 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/87/vyome-reports-transformational-2025-results-company-well-positioned-for-breakout-phase https://ir.vyometx.com/news-events/press-releases/detail/88/livechain-completes-acquisition-of-senior-secured-debt-of-humanyze-an-mit-incubated-ai-enabled-hr-analytics-company Tue, 24 Feb 26 08:00:00 -0500 https://ir.vyometx.com/news-events/press-releases/detail/88/livechain-completes-acquisition-of-senior-secured-debt-of-humanyze-an-mit-incubated-ai-enabled-hr-analytics-company https://ir.vyometx.com/news-events/press-releases/detail/89/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity Wed, 18 Feb 26 09:00:00 -0500 https://ir.vyometx.com/news-events/press-releases/detail/89/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity https://ir.vyometx.com/news-events/press-releases/detail/90/vyome-files-for-vt-1953-orphan-drug-status-furthers-strategic-focus-on-vt-1953-program-over-the-next-6-months Wed, 11 Feb 26 07:00:00 -0500 https://ir.vyometx.com/news-events/press-releases/detail/90/vyome-files-for-vt-1953-orphan-drug-status-furthers-strategic-focus-on-vt-1953-program-over-the-next-6-months https://ir.vyometx.com/news-events/press-releases/detail/91/vyome-successfully-capitalizes-all-vt-1953-funding-requirements-for-initial-phase-3-results Mon, 02 Feb 26 07:00:00 -0500 https://ir.vyometx.com/news-events/press-releases/detail/91/vyome-successfully-capitalizes-all-vt-1953-funding-requirements-for-initial-phase-3-results https://ir.vyometx.com/news-events/press-releases/detail/92/independent-analyst-values-vyomes-vt-1953-at-usd-1-billion-upon-successful-completion-of-phase-3-study Tue, 27 Jan 26 08:00:00 -0500 https://ir.vyometx.com/news-events/press-releases/detail/92/independent-analyst-values-vyomes-vt-1953-at-usd-1-billion-upon-successful-completion-of-phase-3-study